drugset / Trial / NCT07108140
Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of ALPP CAR-T cells in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Timeline
- Start
- 2025-05-20
- Primary completion
- 2025-12-31
- Completion
- 2026-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti ALPP CAR-T cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |